| TAH Drug Code | IGLYC |
|---|---|
| Indications | Preoperatively to inhibit salivation & excessive secretions of the respiratory tract; reversal of neuromuscular blockade; control of upper airway secretions; adjunct in treatment of peptic ulcer. |
| Dosing | Preoperative Adult & children 1 month-12 years 0.002 mg/pound body weight (0.01 mL) IM 30-60 mins before procedure or to be administered with preanesthetic narcotic & sedative. children 1 month-2 years may incresed 0.004 mg/pound body weight (0.02 mL).Intraoperative Adult 0.1 mg (0.5 mL) IV. May repeat at intervals of 2-3 mins. Children 0.002 mg/pound body weight (0.01 mL) IV. Maximum: 0.1 mg (0.5 mL)/dose. May repeat at intervals of 2-3 mins. Reversal of neuromuscular blockade Adult & children 0.2 mg (1 mL) IV for each 1 mg of neostigmine or 5 mg of pyridostigmine. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | In management of peptic ulcer, may be C/I in glaucoma; obstructive uropathy; achalasia; pyloroduodenal stenosis; paralytic ileus; intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Inj Newborn infant <1 mth. |
| Adverse Effects | Dry mouth; urinary hesitancy & retention; blurred vision. Increased ocular tension; tachycardia; palpitations; decreased sweating, loss of taste, headache, nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reaction, drug idiosyncrasies; urticaria; mental confusion. |
| Pregnancy | No (Limited) Human Data – No Relevant Animal Data |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |